Approval for the resolute microtrac zotarolimus-eluting coronary stent system and resolute integrity zotarolimus-eluting coronary stent systems.  These devices are indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length 27 <= mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.2 mm.